Cargando…

Mediastinal staging for non-small cell lung cancer

The staging of mediastinal lymph nodes for lung cancer is crucial for planning treatments or reinterventions. In potentially curable patients the aim of mediastinal staging is to exclude the presence of malignancy in mediastinal lymph nodes with a high level of accuracy while also considering clinic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leiro-Fernández, Virginia, Fernández-Villar, Alberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Review Articles on Multimodal Management of Locally Advanced N2 Non-small Cell Lung Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867740/ https://www.ncbi.nlm.nih.gov/pubmed/33569331 http://dx.doi.org/10.21037/tlcr.2020.03.08

Ejemplares similares

Prognostic factors in potentially resectable stage III non-small cell lung cancer receiving neoadjuvant treatment—a narrative review
por: Calvo, Virginia, et al.
Publicado: (2021)

Induction treatment in patients with stage III non-small cell lung cancer
por: Palmero, Ramón, et al.
Publicado: (2021)

Systematic review of stereotactic body radiotherapy in stage III non-small cell lung cancer
por: Alcibar, Olwen Leaman, et al.
Publicado: (2021)

Neoadjuvant treatment of stage IIIA-N2 in EGFR-Mutant/ALK-rearranged non-small cell lung cancer
por: Reyes, Roxana, et al.
Publicado: (2021)

Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival
por: Casal-Mouriño, Ana, et al.
Publicado: (2021)

Salvage surgery after definitive chemoradiotherapy for patients with non-small cell lung cancer
por: Hamada, Akira, et al.
Publicado: (2021)

Surgery after neoadjuvant immunotherapy in patients with resectable non-small cell lung cancer
por: Huynh, Caroline, et al.
Publicado: (2021)

Emerging biomarkers for neoadjuvant immune checkpoint inhibitors in operable non-small cell lung cancer
por: Pradhan, Monika, et al.
Publicado: (2021)

Minimal invasive surgery in locally advanced N2 non-small cell lung cancer
por: Patané, Ana Karina
Publicado: (2021)

What is the role of consolidative thoracic radiotherapy in the era of chemo-immunotherapy for extensive stage small cell lung cancer?
por: Higgins, Kristin A., et al.
Publicado: (2020)

Surgery for limited stage small cell lung cancer
por: Gergen, Anna K., et al.
Publicado: (2020)

Immunotherapy for extensive stage small cell lung cancer
por: Pacheco, Jose M.
Publicado: (2020)

Systemic therapy for limited stage small cell lung carcinoma
por: Noronha, Vanita, et al.
Publicado: (2020)

The Accuracy of Clinical Staging of Stage I-IIIa Non-Small Cell Lung Cancer: An Analysis Based on Individual Participant Data
por: Navani, Neal, et al.
Publicado: (2019)

Lung cancer specialists' opinions on treatment for stage I non-small cell lung cancer: A multidisciplinary survey
por: Lammers, Austin, et al.
Publicado: (2018)

Prophylactic cranial irradiation or MRI surveillance for extensive stage small cell lung cancer
por: Taylor, James M., et al.
Publicado: (2020)

Stage I and II Small-Cell Lung Cancer—New Challenge for Surgery
por: Doerr, Fabian, et al.
Publicado: (2022)

Persisting Gaps in Optimal Care of Stage III Non-small Cell Lung Cancer: An Australian Patterns of Care Analysis
por: Woodford, Katrina, et al.
Publicado: (2022)

Health Equity in Patients Receiving Durvalumab for Unresectable Stage III Non-Small Cell Lung Cancer in the US Veterans Health Administration
por: Moore, Amanda M, et al.
Publicado: (2023)

Factors influencing the utilization of prophylactic cranial irradiation in patients with limited-stage small cell lung cancer
por: Lok, Benjamin H., et al.
Publicado: (2017)

The prognostic significance of aldehyde dehydrogenase 1A1 (ALDH1A1) and CD133 expression in early stage non-small cell lung cancer
por: Alamgeer, Muhammad, et al.
Publicado: (2013)

Drugs in development for small cell lung cancer
por: Serzan, Michael T., et al.
Publicado: (2020)

Paraneoplastic syndromes in small cell lung cancer
por: Soomro, Zaid, et al.
Publicado: (2020)

Mediastinal radiotherapy after adjuvant chemotherapy for resected non–small cell lung cancer with N2 lymphadenopathy: A novel meta-analysis
por: Harling, Leanne, et al.
Publicado: (2020)

A Prospective Study of Apatinib in Patients with Extensive‐Stage Small Cell Lung Cancer After Failure of Two or More Lines of Chemotherapy
por: Liu, Yutao, et al.
Publicado: (2020)

Small cell lung cancer: updates and future directions
por: Pacheco, Jose M.
Publicado: (2020)

Uptake of minimally invasive surgery and stereotactic body radiation therapy for early stage non-small cell lung cancer in the USA: an ecological study of secular trends using the National Cancer Database
por: Blom, Erik F, et al.
Publicado: (2020)

RET Fusion-Positive Non-small Cell Lung Cancer: The Evolving Treatment Landscape
por: Novello, Silvia, et al.
Publicado: (2023)

Impact of High-Grade Patterns in Early-Stage Lung Adenocarcinoma: A Multicentric Analysis
por: Bertoglio, Pietro, et al.
Publicado: (2022)

Radiosurgery for small-cell lung cancer brain metastases: a review
por: Robin, Tyler P., et al.
Publicado: (2020)

Feasibility study of in vitro drug sensitivity assay of advanced non-small cell lung adenocarcinomas
por: Papp, Emoke, et al.
Publicado: (2020)

Association between time-to-treatment and outcomes in non-small cell lung cancer: a systematic review
por: Hall, Helen, et al.
Publicado: (2022)

Survival of patients with small cell lung cancer undergoing lung resection in England, 1998–2009
por: Lüchtenborg, Margreet, et al.
Publicado: (2014)

Systemic therapy options following first-line chemoimmunotherapy in small-cell lung cancer
por: Pacheco, Jose M.
Publicado: (2020)

PARP inhibitors for small cell lung cancer and their potential for integration into current treatment approaches
por: Barayan, Ranya, et al.
Publicado: (2020)

Navigating Diagnostic and Treatment Decisions in Non‐Small Cell Lung Cancer: Expert Commentary on the Multidisciplinary Team Approach
por: Popat, Sanjay, et al.
Publicado: (2020)

Modeling the Cost-Effectiveness of Adjuvant Osimertinib for Patients with Resected EGFR-mutant Non-Small Cell Lung Cancer
por: Lemmon, Christopher A, et al.
Publicado: (2022)

Pembrolizumab Every 6 Weeks Versus Every 3 Weeks in Advanced Non-Small Cell Lung Cancer
por: Dubé-Pelletier, Maude, et al.
Publicado: (2023)

Integrated care for resected early stage lung cancer: innovations and exploring patient needs
por: Ho, Jan, et al.
Publicado: (2017)

COVID-19 VACCINATION-ASSOCIATED LYMPHADENOPATHY: A DIAGNOSTIC CONUNDRUM IN LUNG CANCER STAGING
por: ELSHAKH, HADYA, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1u9mnvsi43gkjhbvr3mt2p6q7p